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Letters
Intensity-modulated Radiotherapy for the Treatment of Breast Cancer
Sir d In the systematic review of intensity-modulated
radiotherapy (IMRT) in the treatment of breast cancer re-
ported in Clinical Oncology by Dayes and colleagues [1], the
only prospective randomised clinical trial (n ¼ 306) testing
forward-planned IMRT to have reported a 5 year outcome
for adverse effects [2] was excluded on the spurious grounds
that no outcomes of interest were reported (Appendix 3). In
this trial, the control arm patientswere 1.7 timesmore likely
to have a change in breast appearance than the IMRT arm
patients after adjustment for the year of photographic
assessment (95% conﬁdence interval 1.2e2.5, P ¼ 0.008).
In addition, the systematic review discussion gave no
reference to a larger breast randomised trial (n ¼ 1145) also
testing forward-planned IMRT [3]. Patients in the control
group were more likely to develop telangiectasia than
those in the IMRT group (odds ratio ¼ 1.68; 95% conﬁdence
interval ¼ 1.13e2.40; P ¼ 0.009). In patients who had good
surgical cosmesis, those randomised to IMRT were less
likely to deteriorate to a moderate or poor overall cosmesis
than those in the control group (odds ratio¼ 0.63; P¼ 0.061;
95% conﬁdence interval 0.39e1.03). The manuscript for
the updated 5 year results of this study are in preparation.
These omissions are not easily explained, given easy
access to the literature and awareness among colleagues
working in the ﬁeld of the available evidence.
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Call for a Consensus Treatment Approach to the Management of Post-cricoid and
Upper Oesophageal Squamous Cell Carcinoma
Sird Post-cricoid and upper oesophageal squamous cell
carcinomas are uncommon tumours in contiguous
anatomical locations with similar risk factors and histo-
logical features [1,2]. They are currently treated by either
the head and neck or upper gastrointestinal multidisci-
plinary teams according to markedly different site-
specialised treatment protocols.
We identiﬁed 102 post-cricoid and 109 upper oesopha-
geal age- and stage-matched patients presenting with each
site of disease to our institution between 1997 and 2011 and
compared treatment received and outcomes.
In total, 75% of post-cricoid patients, but only 31% of upper
oesophageal patients, were treated with radical intent. Post-
cricoid patients received less concurrent chemoradiotherapy
(31%versus 74%), but a highermean radical radiotherapydose
(64.5 Gy versus 50.2 Gy) to larger planning target volumes
(988.9 cm3 versus 338.1 cm3) than upper oesophageal
patients. All differences were highly signiﬁcant (P < 0.0001).
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